Biologic Therapies in Autoimmune Diseases: A Review of Clinical Efficacy and Safety Trends

Abstract

Biologic therapies for rheumatologic illnesses, aimed at targeting molecules implicated in immune system mechanisms, offer an alternative to conventional treatments such as disease-altering   anti-rheumatic medicines with additional immunosuppressive medications. Nonetheless, the existing limitations of biologic treatments, including the challenges of intravenous administration, the substantial prices of these pharmaceuticals, and the associated side events hinder their widespread use as first-line treatments. This review is an update on the recent research regarding the novel biologic medicines accessible. The review focuses on eight pharmaceuticals: Tocilizumab, Rituximab, Adalimumab, Ustekinumab, Infliximab Belimumab, Vedolizumab, and Secukinumab, utilized in the treatment of rheumatoid arthritis, spondyloarthritis, systemic lupus erythematosus, systemic sclerosis, or vasculitis.